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In the previous issue of Critical Care, we read with interest 
the article by He and colleagues [1] on invasive bronchial-
pulmonary aspergillosis (IBPA) in critically ill patients with 
chronic obstructive respiratory diseases (CORDs).
In this prospective study, the authors, contrary to their 
statement, did not follow the case deﬁ  nitions for ‘probable’ 
invasive pulmonary aspergillosis (IPA) as deﬁ  ned by the 
consensus of the European Organization for Research 
and Treatment of Cancer and the National Institute of 
Allergy and Infectious Diseases Mycoses Study Group 
(EORTC/MSG) [2]. Indeed, EORTC/MSG criteria for 
probable IPA require that all three of the following 
concomitant conditions be fulﬁ  lled: presence of a host 
factor, presence of a clinical criterion, and presence of a 
mycological criterion. In the study group with IBPA, at 
least two patients (patients 4 and 13) did not fulﬁ  ll these 
criteria and thus were erroneously incorporated in the 
case group. Furthermore, only 4 patients (out of 13) had 
histologically proven invasive bronchial aspergillosis, and 
many patients thus may have been erroneously classiﬁ  ed 
in the IBPA group since no autopsy was performed.
Considering the low number of patients with IBPA as 
well as the misclassiﬁ  cation of some of them, we feel that 
providing independent variables predicting IBPA (with 
further extrapolation of a diagnostic algorithm) in 
critically ill patients with CORD is irrelevant.
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We thank Bulpa and Dive for their comments. We agree 
that some cases in our study did not strictly fulﬁ  ll the 
EORTC/MSG diagnostic criteria, mainly for a lack of 
host factors. However, the EORTC/MSG criteria for IPA 
were developed for patients with malignant disease and 
recipients of allogeneic hematopoietic stem cell and 
solid-organ transplants [2]. Owing to the absence of data, 
the criteria do not apply to non-cancer populations. In 
2007, Bulpa and colleagues [3] relied on several case 
reports to propose their deﬁ  nitions of IPA, speciﬁ  cally 
for chronic obstructive pulmonary disease patients and 
isolation of Aspergillus. Th  e diagnoses for 36 patients 
(64%) were classiﬁ  ed as proven in their study, and this 
circumstance conﬁ  rmed the validity of their criteria. As a 
result, their criteria may be more appropriate for IPA in 
future studies with the CORD population.
We agree that additional proven cases are needed to 
avoid the misclassiﬁ  cation of some patients with IBPA. 
However, invasive procedures such as transbronchial 
biopsies are rarely performed in late-stage critically ill 
patients with CORD, and this dramatically limits the 
possibility of collecting histological evidence of IPA. In a 
recent study with the largest series of IPA in patients with 
chronic obstructive pulmonary disease, none of the 53 
cases had a lung biopsy [4]. Th  e biopsy of bronchial 
mucous is less invasive and may give evidence of trachea-
bronchial invasion with Aspergillus. Th   erefore, we prefer 
to do bronchial mucous biopsy rather than transbronchial 
lung biopsy under bronchoscopy for an early diagnosis of 
IBPA in patients with CORD.
Abbreviations
CORD, chronic obstructive respiratory disease; EORTC/MSG, European 
Organization for Research and Treatment of Cancer/National Institute of 
Allergy and Infectious Diseases Mycoses Study Group; IBPA, invasive bronchial-
pulmonary aspergillosis; IPA, invasive pulmonary aspergillosis.
Competing interests
The authors declare that they have no competing interests.
*Correspondence: pierre.bulpa@uclouvain.be
Intensive Care Unit, Mont-Godinne University Hospital, Université Catholique de 
Louvain, Avenue Therasse 1, 5530 Yvoir, Belgium
Bulpa and Dive Critical Care 2011, 15:420 
http://ccforum.com/content/15/2/420
© 2011 BioMed Central LtdPublished: 27 April 2011
References
1.  He H, Ding L, Li F, Zhan Q: Clinical features of invasive bronchial-pulmonary 
aspergillosis in critically ill patients with chronic obstructive respiratory 
diseases: a prospective study. Crit Care 2011, 15:R5.
2.  De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas 
PG, Maertens J, Lortholary O, Kauff  man CA, Denning DW, Patterson TF, 
Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, 
Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, 
Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, et al.: Revised defi  nitions 
of invasive fungal disease from the European Organization for Research 
and Treatment of Cancer/Invasive Fungal Infections Cooperative Group 
and the National Institute of Allergy and Infectious Diseases Mycoses 
Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 
46:1813-1821.
3.  Bulpa P, Dive A, Sibille Y: Invasive pulmonary aspergillosis in patients with 
chronic obstructive pulmonary disease. Eur Respir J 2007, 30:782-800.
4.  Guinea J, Torres-Narbona M, Gijón P, Muñoz P, Pozo F, Peláez T, de Miguel J, 
Bouza E: Pulmonary aspergillosis in patients with chronic obstructive 
pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol 
Infect 2010, 16:870-877.
doi:10.1186/cc10138
Cite this article as: Bulpa P, Dive A: Diagnosis of invasive bronchial-
pulmonary aspergillosis in patients with chronic obstructive respiratory 
diseases. Critical Care 2011, 15:420.
Bulpa and Dive Critical Care 2011, 15:420 
http://ccforum.com/content/15/2/420
Page 2 of 2